目的 探讨养胃舒胶囊联合吉法酯片治疗慢性萎缩性胃炎的临床疗效。方法 将2022年11月—2024年12月石家庄市人民医院收治的慢性萎缩性胃炎患者共计82例纳入研究。按随机数字表法将所有患者分为对照组（41例）、治疗组（41例）。对照组口服吉法酯片，3次/d，2片/次。治疗组在对照组基础上口服养胃舒胶囊，2次/d，2粒/次。两组患者持续治疗3个月。对比患者的临床疗效、胃镜病理评分、胃肠道激素和血清细胞因子。结果 对照组患者的总有效率为80.49%，明显低于治疗组的总有效率95.12%，组间比较差异显著（P＜0.05）。两组治疗后的胃镜病理评分低于治疗前（P＜0.05），治疗组治疗后的胃镜病理评分低于对照组（P＜0.05）。治疗后，两组的胃蛋白酶原比值（PGR）、胃泌素-17（G-17）、生长抑素（SS）均比治疗前高（P＜0.05），且治疗组的PGR、G-17、SS高于对照组（P＜0.05）。两组治疗后的转化生长因子-β1（TGF-β1）、人表皮生长因子（hEGF）、趋化因子C-X3-C-基元配体1（CX3CL1）显著降低，治疗组治疗后的TGF-β1、hEGF、CX3CL1低于对照组（P＜0.05）。结论 养胃舒胶囊联合吉法酯片可提高慢性萎缩性胃炎的临床疗效，减轻胃黏膜病理改变，调节胃肠激素的分泌，延缓纤维化进程。

Objective To explore the clinical efficacy of Yangweishu Capsules combined with Gefitil Tablets in treatment of chronic atrophic gastritis.Methods 82 Patients with chronic atrophic gastritis admitted to Shijiazhuang People's Hospital from November 2022 to December 2024 were included, and were divided into control group (n = 41) and treatment group (n = 41) according to the random number table method. The control group patients took orally Gefitil Tablets, 3 times daily, 2 tablets per time. On the basis of the control group, the treatment group patients took orally Yangweishu Capsules, twice daily, 2 capsules/time. Two groups of patients received continuous treatment for 3 months. The clinical efficacy, gastroscopy pathological score, gastrointestinal hormones, and serum cytokines were compared between two groups.Results The total effective rate of the control group was 80.49%, which was significantly lower than the 95.12% of the treatment group, and the difference between the groups was significant (P < 0.05). The gastroscopy pathological scores in two groups after treatment were lower than those before treatment (P < 0.05), and the gastroscopy pathological scores in the treatment group were lower than those in the control group after treatment (P < 0.05). After treatment, the pepsinogen ratio (PGR), gastrin-17 (G-17), and somatostatin (SS) in two groups were higher than those before treatment (P < 0.05), and the PGR, G-17, and SS in the treatment group were higher than those in the control group (P < 0.05). After treatment, the serum levels of transforming growth factor-β1 (TGF-β1), human epidermal growth factor (hEGF), and chemokine C-X3-C-based ligand 1 (CX3CL1) were significantly reduced in two groups, and the serum levels of TGF-β1, hEGF, and CX3CL1 in the treatment group were lower than those in the control group (P < 0.05).Conclusion The combination of Yangweishu Capsules and Gefitil Tablets can improve the clinical efficacy of chronic atrophic gastritis, alleviate pathological changes in the gastric mucosa, regulate the secretion of gastrointestinal hormones, and delay the fibrosis process.

R975

河北省卫生健康委医学科学研究课题计划项目（20210198）